127 related articles for article (PubMed ID: 38635879)
21. Senolytic targets and new strategies for clearing senescent cells.
Ge M; Hu L; Ao H; Zi M; Kong Q; He Y
Mech Ageing Dev; 2021 Apr; 195():111468. PubMed ID: 33741395
[TBL] [Abstract][Full Text] [Related]
22. Combined inhibition of class 1-PI3K-alpha and delta isoforms causes senolysis by inducing p21
Neuwahl J; Neumann CA; Fitz AC; Biermann AD; Magel M; Friedrich A; Sellin L; Stork B; Piekorz RP; Proksch P; Budach W; Jänicke RU; Sohn D
Cell Death Dis; 2024 May; 15(5):373. PubMed ID: 38811535
[TBL] [Abstract][Full Text] [Related]
23. Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer.
Estepa-Fernández A; García-Fernández A; Lérida-Viso A; Blandez JF; Galiana I; Sancenon-Galarza F; Orzáez M; Martínez-Máñez R
Pharmacol Res; 2023 Jan; 187():106628. PubMed ID: 36566002
[TBL] [Abstract][Full Text] [Related]
24. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
Negi A; Voisin-Chiret AS
Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
[TBL] [Abstract][Full Text] [Related]
25. Elimination of Senescent Osteocytes by Bone-Targeting Delivery of β-Galactose-Modified Maytansinoid Prevents Age-Related Bone Loss.
He Y; Zhang L; Chen X; Liu B; Shao X; Fang D; Lin J; Liu N; Lou Y; Qin J; Jiang Q; Guo B
Adv Healthc Mater; 2024 Mar; 13(8):e2302972. PubMed ID: 38063283
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers.
Vielhauer GA; Swink M; Parelkar NK; Lajiness JP; Wolfe AL; Boger D
Cancer Biol Ther; 2013 Jun; 14(6):527-36. PubMed ID: 23760495
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
Qu Y; Zhang C; Ma X; Gao Y; Liu J; Wu L
Bioorg Med Chem; 2020 Dec; 28(24):115821. PubMed ID: 33091789
[TBL] [Abstract][Full Text] [Related]
28. Galactose conjugated platinum(II) complex targeting the Warburg effect for treatment of non-small cell lung cancer and colon cancer.
Wu M; Li H; Liu R; Gao X; Zhang M; Liu P; Fu Z; Yang J; Zhang-Negrerie D; Gao Q
Eur J Med Chem; 2016 Mar; 110():32-42. PubMed ID: 26807543
[TBL] [Abstract][Full Text] [Related]
29. Far-red Fluorescent Senescence-associated β-Galactosidase Probe for Identification and Enrichment of Senescent Tumor Cells by Flow Cytometry.
Flor A; Pagacz J; Thompson D; Kron S
J Vis Exp; 2022 Sep; (187):. PubMed ID: 36190263
[TBL] [Abstract][Full Text] [Related]
30. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells.
Escriche-Navarro B; Garrido E; Sancenón F; García-Fernández A; Martínez-Máñez R
Acta Biomater; 2024 Mar; 176():405-416. PubMed ID: 38185231
[TBL] [Abstract][Full Text] [Related]
31. BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells.
Buckley S; Shi W; Driscoll B; Ferrario A; Anderson K; Warburton D
Am J Physiol Lung Cell Mol Physiol; 2004 Jan; 286(1):L81-6. PubMed ID: 12959928
[TBL] [Abstract][Full Text] [Related]
32. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
33. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
[TBL] [Abstract][Full Text] [Related]
34. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates.
Fang L; Battisti RF; Cheng H; Reigan P; Xin Y; Shen J; Ross D; Chan KK; Martin EW; Wang PG; Sun D
J Med Chem; 2006 Oct; 49(21):6290-7. PubMed ID: 17034135
[TBL] [Abstract][Full Text] [Related]
35. Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.
Chang M; Gao F; Pontigon D; Gnawali G; Xu H; Wang W
J Am Chem Soc; 2023 Jun; 145(25):14155-14163. PubMed ID: 37327395
[TBL] [Abstract][Full Text] [Related]
36. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
37. Characterization of Induction and Targeting of Senescent Mesenchymal Stromal Cells.
Gresham RCH; Kumar D; Copp J; Lee MA; Leach JK
Tissue Eng Part C Methods; 2022 Jun; 28(6):239-249. PubMed ID: 35438548
[TBL] [Abstract][Full Text] [Related]
38. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
[TBL] [Abstract][Full Text] [Related]
39. Quantitative identification of senescent cells in aging and disease.
Biran A; Zada L; Abou Karam P; Vadai E; Roitman L; Ovadya Y; Porat Z; Krizhanovsky V
Aging Cell; 2017 Aug; 16(4):661-671. PubMed ID: 28455874
[TBL] [Abstract][Full Text] [Related]
40. Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker.
Poblocka M; Bassey AL; Smith VM; Falcicchio M; Manso AS; Althubiti M; Sheng X; Kyle A; Barber R; Frigerio M; Macip S
Sci Rep; 2021 Oct; 11(1):20358. PubMed ID: 34645909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
